Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CNS Response wins third US patent
According to CNS Response, the new patent presents novel use of the company’s protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG
According to CNS Response, the new patent presents novel use of the company’s protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG
According to Metabasis, MB07803 treatment resulted in dose-related, clinically meaningful and statistically significant reductions in day long glycemia (24-hour weighted mean glucose levels) at all doses evaluated (50mg,
Based in Birkerod, Denmark, Mr Moraviec will have global responsibility for the continence and critical care business unit, a new business unit formed following ConvaTec’s integration of Unomedical,
RXi Pharmaceuticals, a discovery-stage biopharmaceutical company, has reported a net loss of $4m, or $0.29 per share, for the fourth quarter of 2008, compared to a net loss
According to Medline, MatriStem, a parchment-like sheet made from specific layers of pig bladder, is a natural extracellular matrix that can be applied to the site of an
Under the alliance agreement, at least eight additional generic drug products will be developed by Epic Pharma and Epic Investments (collectively Epic) at Elite’s facility with the intent
Pursuant to the terms of the agreement, the two companies will develop and market new products based on Bio-Rad’s surface-enhanced laser desorption/ionization (SELDI) technology in combination with Bruker’s
During the 18-month term of the equity financing commitment, Arena may sell newly issued registered shares of its common stock to Azimuth Opportunity at a pre-negotiated discount to
“After having achieved my goal of successfully identifying and acquiring a FDA cleared, CLIA waived product that offers CLX the opportunity to become market leader in an important
US-based medical device company Cook has announced that as part of its global effort to protect its extensive intellectual property portfolio, it will appeal promptly an initial ruling